102 related articles for article (PubMed ID: 8252498)
1. Pharmacology of nilutamide.
Gaillard-Moguilewsky M; de Gery A; Ulmann A
Cancer; 1993 Dec; 72(12 Suppl):3828-9. PubMed ID: 8252498
[No Abstract] [Full Text] [Related]
2. Nilutamide approved for metastatic prostate cancer.
Am J Health Syst Pharm; 1996 Dec; 53(23):2784. PubMed ID: 8957341
[No Abstract] [Full Text] [Related]
3. Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion.
Decensi A; Torrisi R; Marroni P; Pensa F; Padovani P; Boccardo F
Prostate; 1994; 24(1):17-23. PubMed ID: 8290386
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology and clinical studies with RU 23908 (Anandron).
Raynaud JP; Moguilewsky M; Tournemine C; Pottier J; Coussedière D; Salmon J; Husson JM; Bertagna C; Tremblay D; Pendyala L
Prog Clin Biol Res; 1985; 185A():99-120. PubMed ID: 4034583
[No Abstract] [Full Text] [Related]
5. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
Harris MG; Coleman SG; Faulds D; Chrisp P
Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188
[TBL] [Abstract][Full Text] [Related]
6. Nilutamide-induced neutropenia.
Eaton VS; Blackmore TK
BJU Int; 2001 Nov; 88(7):801-2. PubMed ID: 11890258
[No Abstract] [Full Text] [Related]
7. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
Hucher M; de Gery A; Bertagna C
Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510
[No Abstract] [Full Text] [Related]
8. Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ; Holdsworth MT
Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
[TBL] [Abstract][Full Text] [Related]
9. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
Eastham JA; Sartor O
J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
[No Abstract] [Full Text] [Related]
10. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
Kassouf W; Tanguay S; Aprikian AG
J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
[TBL] [Abstract][Full Text] [Related]
11. [Fatal fulminant hepatitis induced by nilutamide (Anandron)].
Pescatore P; Hammel P; Durand F; Bertheau P; Bernuau J; Huc D; Gerbal JL; Degott C; Benhamou JP
Gastroenterol Clin Biol; 1993; 17(6-7):499-501. PubMed ID: 8243938
[TBL] [Abstract][Full Text] [Related]
12. [Complete androgen blockage in the treatment of metastatic prostate cancer].
Matzkin H; Braf Z
Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104
[No Abstract] [Full Text] [Related]
13. Design of antiandrogens and their mechanisms of action: a case study (anandron).
Raynaud JP; Fiet J; Le Goff JM; Martin PM; Moguilewsky M; Ojasoo T
Horm Res; 1987; 28(2-4):230-41. PubMed ID: 3331376
[TBL] [Abstract][Full Text] [Related]
14. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
Janknegt RA
Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and metabolism of nilutamide.
Creaven PJ; Pendyala L; Tremblay D
Urology; 1991; 37(2 Suppl):13-9. PubMed ID: 1992598
[TBL] [Abstract][Full Text] [Related]
16. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
17. The place and the results of monotherapy.
Bonnet P
Acta Urol Belg; 1998 May; 66(2):11-5. PubMed ID: 9633120
[No Abstract] [Full Text] [Related]
18. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
Furr BJ
Horm Res; 1989; 32 Suppl 1():69-76. PubMed ID: 2533159
[TBL] [Abstract][Full Text] [Related]
19. What is an antiandrogen and what is the physiological and pharmacological rationale for combined "castration" + "antiandrogen" therapy.
Moguilewsky M; Cotard M; Proulx L; Tournemine C; Raynaud JP
Prog Clin Biol Res; 1987; 243A():315-40. PubMed ID: 3116549
[No Abstract] [Full Text] [Related]
20. Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?
Decensi A; Torrisi R; Fontana V
Br J Cancer; 1994 Mar; 69(3):617-9. PubMed ID: 8123500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
